Sanofi raises big loan as it plots Genzyme buyout strategy

Sanofi says that regulators have given the company a green light to proceed with its $18.5 billion buyout bid.
Sanofi-Aventis may not be able to get the time of day from Genzyme's board, but the pharma giant says its hostile takeover attempt faces no antitrust concerns in the U.S. Sanofi says that regulators have given the company a green light to proceed with its $18.5 billion buyout bid. That's not likely going to carry much weight at Genzyme, though, where CEO Henri Termeer and the board are bunkering down and urging shareholders to resist what they believe is a lowball bid.
Sanofi, though, is methodically going about the business of doing a deal, even if it can't quite get to the bargaining table yet. Quoting sources, the Financial Times reports that the pharma company had no trouble at all arranging a $15 billion loan syndication in a matter of hours. And that gives Sanofi plenty of cash to change the deal terms at any point it likes. The FT Also makes clear that Sanofi is now focused on winning over a few of Genzyme's biggest investors. As long as Termeer holds the key to the c
Related News
-
News How can pharma achieve ‘Net Zero’? Through driving change in pharma manufacturing
Through the entire product lifecycle – production, consumption and disposal – the pharma industry significantly impacts the environment. -
News Planning for supply chain resilience
Engagement-based strategy could increase resilience of pharma supply chain. -
News Strategies for managing an outsourcing partner
Robust oversight linked to increased efficiency and better communication with outsourcing partners. -
News Updated: CPHI North America 2022 Blog
Follow along for live updates from CPHI North America, taking place in Philadelphia, PA from May 17-19. -
News Greater standardisation needed for effective ESG reporting - Expert panel
Increased transparency and standardisation in ESG reporting frameworks is emerging as a key requirement for investors. -
News MedPharm: Increased investment driving developments in topical drugs market
We caught up with MedPharm at CPHI North America to discuss opportunities in the topical and transdermal products space. -
News Pharmapack Awards 2022: Winners Revealed
The jury assessed a wide range of industry-changing innovations in packaging and drug delivery, ultimately selecting seven winners. -
News What it means to be 'At the heart of Pharma'
Informa Markets colleagues explain the motivations behind CPHI’s rebrand.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance